Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05501340
Other study ID # JD-LK-2022-033-02
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date September 1, 2022
Est. completion date September 1, 2024

Study information

Verified date August 2022
Source Second Affiliated Hospital of Soochow University
Contact Yuehong Kong, Doctor
Phone +8613375183257
Email kkyuehong@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The effect and safety of intraperitoneal infusion of PD-1 inhibitor is unclear for patients with peritoneal metastasis of advanced malignant tumors and malignant ascites. It is planned to determine the safety and efficacy of intraperitoneal infusion of PD-1 inhibitor combination with PRaG therapy.


Description:

Patinets with peritoneal metastasis have limited treatment and poor prognosis. Evidence has shown that there are T lymphocates and macrophages in the ascites microenviroment.We suggested the Intraperitoneal infusion of PD-1 inhibitor might activate T cells and produce anti-tumor effect.The intraperitoneal infusion of PD-1 inhibitorand combined with PRaG(Intravenous injectionof PD-1 inhibitor, Radiotherapy and GM-CSF)might benefit the survival of patients with peritoneal metastasis of advanced malignant tumors with malignant ascites. It is planned to determine the safety in phase I clinical trial. Further through phase II clinical trials, to clarify the effectiveness of this therapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date September 1, 2024
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients > 18 years of age. - Pathologically diagnosed malignant tumor abdominal metastasis with malignant ascites (or ascites exfoliative cytology confirmed malignant peritoneal effusion), without brain metastasis or liver metastasis. The patient had newly diagnosed abdominal metastasis with malignant ascites for no more than 1 month. - Progression on at least one line of prior standard therapy or unsuitability for standard systemic therapy. - No congestive heart failure, unstable angina pectoris, unstable arrhythmia within the past 6 months. - Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-3, and life expectancy 2 months or more. - No previous severe hematopoietic function, heart, lung, liver, kidney dysfunction and immunodeficiency. - One week before enrollment, the absolute value of peripheral blood T total lymphocytes = 0.5 times the lower limit of normal, the absolute number of CD8 + T cells = 200/uL, neutrophils = 1.0 × 109/L; AST and ALT = 3.0 times the upper limit of normal; creatinine = 1.5 times the upper limit of normal or creatinine clearance = 50 mL/min, serum albumin = 30 g/L. After treatment, the indicators are allowed to reach the above criteria and last for 2 weeks. Transfusion therapy or granulocyte stimulating factor therapy is not allowed before treatment. - Patients must have the ability to understand and voluntarily sign an informed consent form. Exclusion Criteria: - Pregnant or lactating women. - Patients with a history of other malignant diseases in the last 2 years, except cured skin cancer and carcinoma in situ. - Patients with a history of uncontrolled epilepsy, central nervous system diseases or mental disorders, whose clinical severity may hinder the signing of informed consent or affect the patient's compliance with drug treatment as judged by the investigator. - Clinically significant (ie, active) heart disease, such as symptomatic coronary heart disease, congestive heart failure New York Heart Association (NYHA) Class II or greater, or severe arrhythmia requiring drug intervention, or a history of myocardial infarction within the last 12 months. - Organ transplantation requiring immunosuppressive therapy. - Known active infection, or significant hematological, renal, metabolic, gastrointestinal, endocrine function or metabolic disorders, or other serious uncontrolled concomitant diseases as judged by the investigator. - Hypersensitivity to any component of the study drug. - History of immunodeficiency, including positive HIV test or other acquired, congenital immunodeficiency diseases, or a history of organ transplantation, or other related diseases requiring long-term oral hormone therapy (greater than 10 mg/d prednisone). - Patients who are in the period of acute and chronic tuberculosis infection (patients with positive T-spot test and suspicious tuberculosis lesions on chest radiography), are in the period of acute hepatitis infection or have chronic hepatitis B virus copy number higher than the normal range. - There are contraindications for abdominal paracentesis, including coagulation dysfunction such as severe thrombocytopenia, severe intestinal dilatation and enteroparalysis, and peritoneal adhesion. - Patients previously treated with immune checkpoint inhibitors and discontinued due to drug-related toxicity. - Other conditions considered unsuitable by the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Serplulimab
PD-1 inhibitor (HLX10, serplulimab) 100mg intraperitoneal infusion every two weeks after radiotherapy PD-1 inhibitor (HLX10, serplulimab) 3mg/kg intravenous infusion within one week after radiotherapy every two weeks
Molgramostim
200ug qd subcutaneous injection for 7 days
Radiation:
Hypofractionated radiotherapy/Sterotactic body radiotherapy
8Gy*3f

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Second Affiliated Hospital of Soochow University

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicity(DLT)by CTCAE5.0 CTCAE is widely accepted throughout the oncology community as the standard classification and severity grading scale for adverse events in cancer therapy clinical trials and other oncology settings 6 months (phase 1)
Primary Treatment Related Severe Adverse Effects Number of participants with treatment-related severe adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 6 months (phase 1)
Primary OS overall survival time 12 months (phase 2)
Secondary OS overall survival time 12 months (phase 1)
Secondary PFS progression-free survival 12 months (phase 1/2)
Secondary ascites control rate ascites control rate 12 months(phase 1/2 )
See also
  Status Clinical Trial Phase
Recruiting NCT06200376 - A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer Phase 1
Completed NCT04051112 - Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites Phase 1
Completed NCT00836654 - Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group Phase 2/Phase 3
Not yet recruiting NCT03550560 - EUS-Guided Drainage of Refractory Malignant Ascites
Recruiting NCT04501744 - A Study of M701 (EpCAM and CD3) in Malignant Ascites Phase 1
Terminated NCT00028782 - EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer N/A
Recruiting NCT05477927 - Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases Phase 1
Active, not recruiting NCT06266091 - Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody Phase 2
Withdrawn NCT04076566 - Malignant Ascites Alfapump® Study
Enrolling by invitation NCT01854866 - Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion Phase 2
Recruiting NCT03230708 - Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites Phase 1/Phase 2
Completed NCT01327235 - Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites Phase 2
Recruiting NCT06432296 - Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody Phase 3
Not yet recruiting NCT04985357 - Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs
Terminated NCT02496286 - Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites Phase 1
Completed NCT01532427 - ALFApump System Post Marketing Surveillance Registry
Completed NCT00326885 - Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites Phase 2
Recruiting NCT02530398 - A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites Phase 1
Withdrawn NCT00908219 - A Study of Bevacizumab to Prevent Malignant Ascites Phase 2
Recruiting NCT06016179 - Tocilizumab Delivered Via Pleural and Peritoneal Catheters in Patients With Advanced Metastatic Cancer Phase 1